Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1994-02-14
1996-09-24
Cunningham, Thomas M.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
4352402, 530326, 530327, 530328, 530828, 4241851, 4242771, C12N 508, C07K 706, C07K 708, G01N 3368
Patent
active
055589952
ABSTRACT:
The invention relates to the identification of complexes of HLA-C-clone 10 and MAGE-1 derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5462871 (1995-10-01), Boon-Falleur et al.
Ding, M. et al., Biochem. Biophys. Res. Comm. 202:549-555, "Cloning and analysis of MAGE-1-related genes".
van der Bruggen et al., "A Gene Encoding An Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma", Sci. 254: 1643-1647 (Dec. 13, 1991).
Sibille et al., "Structure of the Gene of Tum-Transplantation Antigen P198: A Point Mutation Generates A New Antigenic Peptide", J. Exp. Med. 172: 35-45 (Jul., 1990).
Szikora et al., "Structure of the gene of Tum-transplantation antigen P35B: presence of a point mutation in the antigenic allele", EMBO J 9(4): 1041-1050 (1990).
Van den Eynde et al., "Presence on a Human Melanoma of Multiple Antigens Recognized by Autologous CTL", Int. J. Cancer 44: 634-640 (1989).
Lurquin et al., "Structure of the Gene of Tum-Transplantation Antigen P91A: The Mutated Exon Encodes a Peptide Recognized with L.sup.d by Cytolytic T Cells", Cell 58: 293-305 (Jul. 28, 1989).
Wolfel et al., "Immunogenic tum-variants obtained by mutagenesis of mouse mastocytoma" P815, Immunogenetics 26: 178-187 (1987).
Boon et al., "Genes Coding for Tum-Transplantation Antigens A Model for TSTA" in Immunology, vol. VII (Springer Verlag, 1989), pp. 1063-1070.
DePlaen et al., "Immunogenic tum-variants of mouse tumor P815: Cloning of the gene of tum-antigen P91A and identification of the tum-mutation", Proc. Natl. Acad. Sci. USA 85: 2274-2278 (Apr. 1988).
Boon et al., "Immunogenic Variants Obtained by Mutagenesis of Mouse Mastocytoma" P815:, J. Exp. Med. 152: 1184-1193 (Nov. 1990).
Greenberg, "Therapy of Murine Leukemia With Cyclophosphamide and Immune LYT-2+ Cells: Cytolytic T Cells Can Mediate Eradication of Disseminated Leukemia", J. Immunol. 136(5): 1917-1922 (1986).
Kast, et al., "Eradication of Adeno-Virus El-Induced Tumors by ElA-Specific Cytolytic T Lymphocytes", Cell 59: 604-14 (Nov. 17, 1989).
Lynch, et al., "Immunotherapeutic elimination of syngeneic tumors in vivo by cytotoxic T lymphocytes generated in vitro from lymphocytes from the draining lymph nodes of tumor-bearing mice", Eur. J. Immunol. 21: 1403-1410 (1991).
Chen, et al., ":Human papilloma type 16 nucleoprotein E7 is a tumor rejection antigen", Proc. Natl. Acad. Sci. USA 88: 110-114 (Jan. 1991).
Riddell, et al., "Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones", Science 257: 236-241 (Jul. 10, 1992).
Boon-Falleur Thierry
van der Bruggen Pierre
Cunningham Thomas M.
Ludwig Institute for Cancer Research
LandOfFree
Peptides which are derived from tumor rejection antigen precurso does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides which are derived from tumor rejection antigen precurso, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides which are derived from tumor rejection antigen precurso will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1927862